8-K filed December 20, 2023, 6:59 PM ET ticker BMRN CIK 0001048477

other material confidence high sentiment positive materiality 0.75

BioMarin settles with Elliott; appoints 3 new directors, forms strategic review committee

BIOMARIN PHARMACEUTICAL INC

Board expanded to 15 directors; appoints Barbara Bodem, Athena Countouriotis, Mark Enyedy as independent directors effective Dec 27, 2023.
New Strategic and Operating Review Committee chaired by Richard Meier; includes CEO Alexander Hardy and Maykin Ho; to review business, strategy, and capital allocation.
Cooperation agreement with Elliott includes standstill, voting commitments, and mutual non-disparagement; Elliott supports the changes.
Company commits to holding an investor day in 2024 after committee recommendations; Elliott entered into information-sharing agreement for JPM conference and earnings.

item 1.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Barbara Bodem

director

BMRN · BIOMARIN PHARMACEUTICAL INC

Effective: 2023-12-27
Filed: December 20, 2023, 6:59 PM ET

On December 20, 2023, the size of the Board was expanded from 12 to 15 members in order to allow for the Board to appoint each of Ms. Bodem, Dr. Countouriotis and Mr. Enyedy to serve as a member of the Board, effective on December 27, 2023.

Appointed

Athena Countouriotis

director

BMRN · BIOMARIN PHARMACEUTICAL INC

Effective: 2023-12-27
Filed: December 20, 2023, 6:59 PM ET

On December 20, 2023, the size of the Board was expanded from 12 to 15 members in order to allow for the Board to appoint each of Ms. Bodem, Dr. Countouriotis and Mr. Enyedy to serve as a member of the Board, effective on December 27, 2023.

Appointed

Mark Enyedy

director

BMRN · BIOMARIN PHARMACEUTICAL INC

Effective: 2023-12-27
Filed: December 20, 2023, 6:59 PM ET

On December 20, 2023, the size of the Board was expanded from 12 to 15 members in order to allow for the Board to appoint each of Ms. Bodem, Dr. Countouriotis and Mr. Enyedy to serve as a member of the Board, effective on December 27, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Barbara Bodem was appointed as director at BIOMARIN PHARMACEUTICAL INC.

Action: appointed
Role: director

Exact text from the filing

On December 20, 2023, the size of the Board was expanded from 12 to 15 members in order to allow for the Board to appoint each of Ms. Bodem, Dr. Countouriotis and Mr. Enyedy to serve as a member of the Board, effective on December 27, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Athena Countouriotis was appointed as director at BIOMARIN PHARMACEUTICAL INC.

Action: appointed
Role: director

Exact text from the filing

On December 20, 2023, the size of the Board was expanded from 12 to 15 members in order to allow for the Board to appoint each of Ms. Bodem, Dr. Countouriotis and Mr. Enyedy to serve as a member of the Board, effective on December 27, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Mark Enyedy was appointed as director at BIOMARIN PHARMACEUTICAL INC.

Action: appointed
Role: director

Exact text from the filing

On December 20, 2023, the size of the Board was expanded from 12 to 15 members in order to allow for the Board to appoint each of Ms. Bodem, Dr. Countouriotis and Mr. Enyedy to serve as a member of the Board, effective on December 27, 2023.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BIOMARIN PHARMACEUTICAL INC entered into Cooperation Agreement with Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P. (collectively, “Elliott”) (effective 2023-12-20).

Action: entry
Counterparty: Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P. (collectively, “Elliott”)
Effective: 2023-12-20

Exact text from the filing

On December 20, 2023, BioMarin Pharmaceutical Inc. (the “Company”) announced that it had entered into a Cooperation Agreement (the “Cooperation Agreement”) with Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P. (collectively, “Elliott”)

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

BIOMARIN PHARMACEUTICAL INC filing history →

Source: SEC EDGAR

accession 0001193125-23-300042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.